Analysis of the curative efficacy in patients with chronic hepatitis B treated with entecavir

Objective To evaluate the curative efficacy in patients with chronic hepatitis B(CHB)treated with eraecavir(ETV).Method 33 patients with CHB(7 HBV-chronic carriers,12 mild cases and 14 moderate cases)were treated with entecavir 0.5 mg/d and detected serum HBV DNA,ALT,AST level and HBeAg seroconversion.Results Serum HBV DNA levels of 3 groups were dropped gradually with the therapy.The average declining counts compared with the baseline were increased too.There were no significant differences in the 3 groups compared with each other.At week 24 after treatment,the rates of HBV DNA reduced to negative were 57.1%,75.0%and 100.0%in HBV-chronic carriers group,mild group and moderate group respectively.The rates of HBV DNA reduced to negative in moderate group were higher than that of in HBV-chronic carriers group at 12,24,36 weeks(P<0.05).The rate of HBV DNA reduced to negative in moderate group was higher than that of in mild group at 12 weeks only(P<0.01).5 cases(35.7%)procured HBeAg seroconversion at 48 weeks in moderate group.4 cases(33.3%)procured HBeAg seroconversion at 48 weeks in mild group.ALT/AST recovered to normal in mild group at 36 weeks,in moderate group at 24 weeks respectively.Conclusions ETV is efficacy and safety in patients with chronic hepatitia B. Key words: Hepatiti B,chronic; Entecavir; Curative efficacy